Clicky

Capricor Therapeutics, Inc.(CAPR) News

Date Title
May 7 Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 6 Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
Apr 17 When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
Mar 27 High Growth Tech Stocks In The US Market With Promising Potential
Mar 11 Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Mar 10 FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
Feb 17 High Growth Tech Stocks In The United States To Watch
Feb 10 Capricor Therapeutics to Participate in Upcoming Investor Conferences
Jan 3 CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Jan 2 Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Oct 4 Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
Oct 3 Is Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts?
Sep 26 High Growth Tech Stocks To Watch In September 2024
Jul 31 Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
Jun 25 CORRECTION: Capricor Therapeutics
Jun 25 Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Jun 4 Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
May 14 Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 13 Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
May 13 Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update